<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04814472</url>
  </required_header>
  <id_info>
    <org_study_id>B-0409-102</org_study_id>
    <nct_id>NCT04814472</nct_id>
  </id_info>
  <brief_title>Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations</brief_title>
  <official_title>A Two-Part, Open-Label, Crossover, Bioavailability Study Comparing Tablet and Oral Solution Formulations of BLD-0409 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blade Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blade Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Two-Part, Open-Label, Crossover, Bioavailability Study Comparing Tablet and Oral Solution&#xD;
      Formulations of BLD-0409 in Healthy Volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics&#xD;
      (PD) of two oral formulations of BLD-0409, tablet and solution, in healthy volunteers (HV).&#xD;
&#xD;
      The study consists of two parts:&#xD;
&#xD;
      Part 1: A randomized, open-label, 3-period, 6-sequence, complete crossover study with at&#xD;
      least 3-day washout between treatment periods comparing oral solution formulation to tablet&#xD;
      formulation.&#xD;
&#xD;
      Part 2: A randomized, open-label, 4-period, 4-sequence, complete crossover study with at&#xD;
      least 3-day washout between treatment periods evaluating single ascending doses of tablet&#xD;
      formulation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 16, 2021</start_date>
  <completion_date type="Actual">November 3, 2021</completion_date>
  <primary_completion_date type="Actual">August 17, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the drug concentration-time curve from time zero to the last measurable concentration (AUC0-last)</measure>
    <time_frame>Up to 16 days</time_frame>
    <description>Measured by plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed drug concentration (Cmax)</measure>
    <time_frame>Up to 16 days</time_frame>
    <description>Measured by plasma concentration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Relative Bioavailability</condition>
  <arm_group>
    <arm_group_label>Oral Solution vs. Tablet Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There will be 3 treatments, each single dose administered based on the treatment sequence with at least a 3 day washout between treatments:&#xD;
Treatment A: 750 mg BLD-0409 oral solution formulation (solution) under fasting conditions.&#xD;
Treatment B: 750 mg BLD-0409 tablet formulation (3 x 250 mg tablets) under fasting conditions.&#xD;
Treatment C: 750 mg BLD-0409 tablet formulation (3 x 250 mg tablets) under fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tablet Formulation Dose Proportionality</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There will be 4 treatments, each single dose administered under fed conditions (standard meal) based on the treatment sequence with at least a 3 day washout between treatments:&#xD;
Treatment A: 250 mg BLD-0409 tablet formulation (1 x 250 mg tablet).&#xD;
Treatment B: 500 mg BLD-0409 tablet formulation (2 x 250 mg tablet).&#xD;
Treatment C: 750 mg BLD-0409 tablet formulation (3 x 250 mg tablet).&#xD;
Treatment D: 1000 mg BLD-0409 tablet formulation (4 x 250 mg tablet).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLD-0409</intervention_name>
    <description>Randomized to active product.</description>
    <arm_group_label>Oral Solution vs. Tablet Formulation</arm_group_label>
    <arm_group_label>Tablet Formulation Dose Proportionality</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants are eligible to be included in the study only if all of the following criteria&#xD;
        apply:&#xD;
&#xD;
        Age and Gender&#xD;
&#xD;
          1. Male and female participants 18-55 years of age (inclusive) at the time of signing the&#xD;
             PICF.&#xD;
&#xD;
             Diagnosis and disease characteristics&#xD;
&#xD;
          2. Participants must be in good general health, in the opinion of the Investigator, with&#xD;
             no significant medical history, have no clinically significant abnormalities on&#xD;
             physical examination at Screening, and/or before administration of the initial dose of&#xD;
             study drug.&#xD;
&#xD;
          3. Participants must have clinical laboratory values within normal ranges or &lt; 1.2 times&#xD;
             upper limit of normal (ULN) as specified by the testing laboratory.&#xD;
&#xD;
          4. Body mass index (BMI) 18 to â‰¤ 32 kg/m2.&#xD;
&#xD;
             Reproductive Considerations&#xD;
&#xD;
          5. Use of acceptable contraception.&#xD;
&#xD;
          6. Females of childbearing potential must have a negative serum pregnancy test at&#xD;
             Screening and a negative urine pregnancy test on Day -1. Females not of childbearing&#xD;
             potential must be surgically infertile or post-menopausal (defined as cessation of&#xD;
             regular menstrual periods for at least 12 months), confirmed by follicle-stimulating&#xD;
             hormone (FSH) level &gt; 40 mIU/mL at Screening.&#xD;
&#xD;
             Informed Consent&#xD;
&#xD;
          7. Participants must provide signed informed consent prior to study entry and have the&#xD;
             ability and willingness to attend and comply with the necessary visits at the study&#xD;
             site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants meeting ANY of the following exclusion criteria are NOT eligible to be&#xD;
        randomized into the study:&#xD;
&#xD;
        Medical Conditions&#xD;
&#xD;
          1. Recent (less than 6 weeks) wound, or presence of an ongoing non-healing skin wound.&#xD;
&#xD;
          2. Presence of any underlying physical or psychological medical condition that, in the&#xD;
             opinion of the Investigator, would make it unlikely that the participant will complete&#xD;
             the study per protocol.&#xD;
&#xD;
          3. Active malignancy and/or history of malignancy in the past 5 years, with the exception&#xD;
             of completely excised non-melanoma skin cancer or low grade cervical intraepithelial&#xD;
             neoplasia.&#xD;
&#xD;
          4. Serious local or systemic infection within 1 month of Screening requiring antibiotic&#xD;
             treatment or history of recurrent infections.&#xD;
&#xD;
          5. Surgery within the past 3 months prior to the first study drug administration&#xD;
             determined by the Investigator to be clinically relevant.&#xD;
&#xD;
             Diagnostic Assessments&#xD;
&#xD;
          6. Positive for human immunodeficiency virus (HIV) antibody or antigen.&#xD;
&#xD;
          7. Positive hepatitis C virus (HCV) antibody or positive hepatitis B surface antigen&#xD;
             (HBsAg).&#xD;
&#xD;
          8. Systolic blood pressure (BP) &gt; 150 mmHg or &lt; 90 mmHg or diastolic BP &gt; 90 mmHg or &lt; 50&#xD;
             mmHg at Screening with one repeat allowed per the Investigator's discretion at&#xD;
             Screening and Day -1 (Period 1).&#xD;
&#xD;
          9. Heart rate &lt; 40 beats per minute (bpm) or &gt; 100 bpm at Screening.&#xD;
&#xD;
         10. Prolonged QT interval corrected by Fridericia's formula (QTcF) (&gt; 450 ms for males and&#xD;
             &gt; 470 ms for females), cardiac arrhythmia, or any clinically significant abnormality&#xD;
             in the resting ECG, as judged by the Investigator.&#xD;
&#xD;
         11. Females with heavy menstruating cycles and borderline-low iron studies.&#xD;
&#xD;
             Prior Therapy&#xD;
&#xD;
         12. All prescription and over the counter medications (including herbal medications),&#xD;
             except for non-estrogen contraceptives, are prohibited within 7 days prior to the&#xD;
             first study drug administration and throughout the entire duration of the study.&#xD;
&#xD;
         13. Any estrogen-containing products, e.g., contraceptives, patch, cream, implants within&#xD;
             14 days prior to the first study drug administration.&#xD;
&#xD;
             Prior/Concurrent Clinical Study Experience&#xD;
&#xD;
         14. Administration of investigational product in another study within 30 days prior to the&#xD;
             first study drug administration, or five half-lives, whichever is longer.&#xD;
&#xD;
             Other Exclusions&#xD;
&#xD;
         15. Significant weight loss or gain between Screening and first study drug administration.&#xD;
&#xD;
         16. Blood donation or significant blood loss within 60 days prior to the first study drug&#xD;
             administration.&#xD;
&#xD;
         17. Plasma donation within 7 days prior to the first study drug administration.&#xD;
&#xD;
         18. Females who are pregnant or breastfeeding.&#xD;
&#xD;
         19. Diets that could alter metabolism (i.e., high protein, Slim FastÂ®, NutrisystemÂ®, etc.)&#xD;
             within 7 days prior first study drug administration.&#xD;
&#xD;
         20. History or presence of alcohol or drug abuse (including recreational marijuana use)&#xD;
             within the 1 year prior to the first study drug administration, and unwillingness to&#xD;
             be totally abstinent during the dosing period.&#xD;
&#xD;
         21. Positive urine drug screen/alcohol breath test at Day -1 (admission).&#xD;
&#xD;
         22. Intake of alcohol or caffeine-containing products from 48 hours before first study&#xD;
             drug administration through the EOS visit.&#xD;
&#xD;
         23. Active smokers and users of nicotine-containing products.&#xD;
&#xD;
         24. Failure to satisfy the Investigator of fitness to participate for any other reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Argent, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scientia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scientia Clinical Research</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

